Lucia Brilli1, Riccardo Danielli2, Cristina Ciuoli1, Luana Calabrò2, Anna Maria Di Giacomo2, Alfonso Cerase3, Patrizia Paffetti1, Fausta Sestini1, Brunetta Porcelli4, Michele Maio2, Furio Pacini5. 1. Section of Endocrinology, Department of Medical, Surgical and Neurological sciences, University of Siena, Siena, Italy. 2. Medical Oncology and Immunotherapy Unit, Department of Oncology, Istituto Toscano Tumori, University of Siena, Siena, Italy. 3. Unit of Neuroimaging and Neurointervention, Department of Neurological and Sensorineural Sciences, Azienda Ospedaliera Universitaria Senese, Siena, Italy. 4. Department of Medical Biotechnologies, Biochemistry Division, University of Siena, UOC Laboratorio Patologia Clinica, Azienda Ospedaliera Universitaria Senese, Siena, Italy. 5. Section of Endocrinology, Department of Medical, Surgical and Neurological sciences, University of Siena, Siena, Italy. pacini8@unisi.it.
Abstract
OBJECTIVE: Ipilimumab is a human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4, that has been shown to significantly improve survival in patients with metastatic melanoma. Blocking cytotoxic T-lymphocyte antigen-4 elicits T cell activation, proliferation and anti-tumor response, but can also trigger immune-related adverse events. Among immune-related endocrinopathies, hypophysitis represents the most frequent, with an incidence up to 17% in patients treated with ipilimumab. DESIGN AND METHODS: We report nine cases of ipilimumab-induced hypophysitis in a cohort of 273 patients treated with ipilimumab between 2006 and 2015, as part of clinical trials or after its marketing. Thyroid function tests were scheduled at screening and during follow up (every 21 days) in all patients. Cortisol, adrenocorticotropic hormone, follicle-stimulating hormone, luteinizing hormone, and estradiol (for females) or testosterone (for males), prolactin, growth hormone, insulin-like growth factor 1 were measured only in case of clinical suspicion. RESULTS: The incidence of hypophysitis was 3.3%. The most frequent pituitary failure was adrenocorticotropic hormone and thyroid stimulating hormone secretion with a complete recovery of thyroid stimulating hormone, but not of adrenocorticotropic hormone during follow up. All patients had negative pituitary antibodies. The main symptoms at diagnosis were fatigue and headache. CONCLUSION: Clinicians should be aware about the risk of hypophysitis during treatment with immune check-point inhibitors and the necessity of investigating pituitary function during therapy. Pituitary magnetic resonance imaging does not seem pivotal for a definite diagnosis if not performed at the onset of disease.
OBJECTIVE:Ipilimumab is a human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4, that has been shown to significantly improve survival in patients with metastatic melanoma. Blocking cytotoxic T-lymphocyte antigen-4 elicits T cell activation, proliferation and anti-tumor response, but can also trigger immune-related adverse events. Among immune-related endocrinopathies, hypophysitis represents the most frequent, with an incidence up to 17% in patients treated with ipilimumab. DESIGN AND METHODS: We report nine cases of ipilimumab-induced hypophysitis in a cohort of 273 patients treated with ipilimumab between 2006 and 2015, as part of clinical trials or after its marketing. Thyroid function tests were scheduled at screening and during follow up (every 21 days) in all patients. Cortisol, adrenocorticotropic hormone, follicle-stimulating hormone, luteinizing hormone, and estradiol (for females) or testosterone (for males), prolactin, growth hormone, insulin-like growth factor 1 were measured only in case of clinical suspicion. RESULTS: The incidence of hypophysitis was 3.3%. The most frequent pituitary failure was adrenocorticotropic hormone and thyroid stimulating hormone secretion with a complete recovery of thyroid stimulating hormone, but not of adrenocorticotropic hormone during follow up. All patients had negative pituitary antibodies. The main symptoms at diagnosis were fatigue and headache. CONCLUSION: Clinicians should be aware about the risk of hypophysitis during treatment with immune check-point inhibitors and the necessity of investigating pituitary function during therapy. Pituitary magnetic resonance imaging does not seem pivotal for a definite diagnosis if not performed at the onset of disease.
Authors: Ajay V Maker; James C Yang; Richard M Sherry; Suzanne L Topalian; Udai S Kammula; Richard E Royal; Marybeth Hughes; Michael J Yellin; Leah R Haworth; Catherine Levy; Tamika Allen; Sharon A Mavroukakis; Peter Attia; Steven A Rosenberg Journal: J Immunother Date: 2006 Jul-Aug Impact factor: 4.456
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Mabel Ryder; Margaret Callahan; Michael A Postow; Jedd Wolchok; James A Fagin Journal: Endocr Relat Cancer Date: 2014-03-07 Impact factor: 5.678
Authors: Le Min; Frank Stephen Hodi; Anita Giobbie-Hurder; Patrick A Ott; Jason J Luke; Hilary Donahue; Meredith Davis; Rona S Carroll; Ursula B Kaiser Journal: Clin Cancer Res Date: 2014-12-23 Impact factor: 12.531
Authors: Shintaro Iwama; Alessandra De Remigis; Margaret K Callahan; Susan F Slovin; Jedd D Wolchok; Patrizio Caturegli Journal: Sci Transl Med Date: 2014-04-02 Impact factor: 17.956
Authors: Alexander T Faje; Ryan Sullivan; Donald Lawrence; Nicholas A Tritos; Riley Fadden; Anne Klibanski; Lisa Nachtigall Journal: J Clin Endocrinol Metab Date: 2014-07-31 Impact factor: 5.958
Authors: Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani Journal: Clin Diabetes Endocrinol Date: 2019-01-22
Authors: Ha Nguyen; Komal Shah; Steven G Waguespack; Mimi I Hu; Mouhammed Amir Habra; Maria E Cabanillas; Naifa L Busaidy; Roland Bassett; Shouhao Zhou; Priyanka C Iyer; Garrett Simmons; Diana Kaya; Marie Pitteloud; Sumit K Subudhi; Adi Diab; Ramona Dadu Journal: Endocr Relat Cancer Date: 2021-06-02 Impact factor: 5.678